Retraction notice to: Sensitization of squamous cell carcinoma to cisplatin induced killing by natural agents (Cancer Letters (2009) 278(2) (201–209), (S0304383509000287), (10.1016/j.canlet.2009.01.009));Sensitization of squamous cell carcinoma to cisplatin induced killing by natural agents

Cancer Letters

Volumn 278, Issue 2, 2009, Pages 201-209

  Ali, Shadan ^a   Varghese, Lalee ^b   Pereira, Lucio ^a   Tulunay Ugur, Ozlem E ^a   Kucuk, Omer ^a   Carey, Thomas E ^c   Wolf, Gregory T ^c   Sarkar, Fazlul H ^b  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

3,3 Dindolylmethane; Cisplatin resistance; G2535; NF B; Uterine cervix cancer

Indexed keywords

3,3 DIINDOLYLMETHANE; CISPLATIN; G2535; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOFLAVONE; METHANE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL GROWTH; CELL SURVIVAL; CELL VIABILITY; CLONOGENIC ASSAY; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DNA; GENISTEIN; HUMANS; INDOLES; ISOFLAVONES; MICROTUBULE-ASSOCIATED PROTEINS; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 64649088510     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2018.03.018     Document Type: Erratum

References (40)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., and Thun M.J. Cancer statistics. CA Cancer J. Clin. 58 (2008) 71-96
2. Vokes E.E., Haraf D.J., and Kies M.S. The use of concurrent chemotherapy and radiotherapy for locoregionally advanced head and neck cancer. Semin. Oncol. 27 (2000) 34-38
3. Merrill R.M., Capocaccia R., Feuer E.J., and Mariotto A. Cancer prevalence estimates based on tumour registry data in the Surveillance, Epidemiology, and End Results (SEER) program. Int. J. Epidemiol. 29 (2000) 197-207
4. Castellsague X. Natural history and epidemiology of HPV infection and cervical cancer. Gynecol. Oncol. 110 (2008) S4-S7
5. Longuet M., Beaudenon S., and Orth G. Two novel genital human papillomavirus (HPV) types HPV68 and HPV70, related to the potentially oncogenic HPV39. J. Clin. Microbiol. 34 (1996) 738-744
6. Bauer J.A., Kumar B., Cordell K.G., Prince M.E., Tran H.H., Wolf G.T., Chepeha D.B., Teknos T.N., Wang S., Eisbruch A., Tsien C.I., Urba S.G., Worden F.P., Lee J., Griffith K.A., Taylor J.M., D'Silva N., Wang S.J., Wolter K.G., Henson B., Fisher S.G., Carey T.E., and Bradford C.R. Targeting apoptosis to overcome cisplatin resistance: a translational study in head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 69 (2007) S106-S108
7. Lee T.K., Poon R.T., Wo J.Y., Ma S., Guan X.Y., Myers J.N., Altevogt P., and Yuen A.P. Lupeol suppresses cisplatin-induced nuclear factor-kappaB activation in head and neck squamous cell carcinoma and inhibits local invasion and nodal metastasis in an orthotopic nude mouse model. Cancer Res. 67 (2007) 8800-8809
8. Bernier J., and Vrieling C. Docetaxel in the management of patients with head and neck squamous cell carcinoma. Expert. Rev. Anticancer Ther. 8 (2008) 1023-1032
9. Al-Sarraf M. Chemotherapy strategies in squamous cell carcinoma of the head and neck. Crit. Rev. Oncol. Hematol. 1 (1984) 323-355
10. Glick J.H., Zehngebot L.M., and Taylor S.G. Chemotherapy for squamous cell carcinoma of the head and neck: a progress report. Am. J. Otolaryngol. 1 (1980) 306-323
11. Tannock I.F. Chemotherapy for head and neck cancer. J. Otolaryngol. 13 (1984) 99-104
12. Pignon J.P., Bourhis J., Domenge C., and Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data, MACH-NC Collaborative Group, meta-analysis of chemotherapy on head and neck cancer. Lancet 355 (2000) 949-955
13. Pignon J.P., Baujat B., and Bourhis J. Individual patient data meta-analyses in head and neck carcinoma: what have we learnt?. Cancer Radiother. 9 (2005) 31-36
14. Kim E.S., Kies M., and Herbst R.S. Novel therapeutics for head and neck cancer. Curr. Opin. Oncol. 14 (2002) 334-342
15. Chen J.Y., Yan Z., Shen C., Fitzpatrick D.P., and Wang M. A systems biology approach to the study of cisplatin drug resistance in ovarian cancers. J. Bioinform. Comput. Biol. 5 (2007) 383-405
16. Kartalou M., and Essigmann J.M. Mechanisms of resistance to cisplatin. Mutat. Res. 478 (2001) 23-43
17. Venkatraman M., Anto R.J., Nair A., Varghese M., and Karunagaran D. Biological and chemical inhibitors of NF-kappaB sensitize SiHa cells to cisplatin-induced apoptosis. Mol. Carcinog. 44 (2005) 51-59
18. Li Y., Ahmed F., Ali S., Philip P.A., Kucuk O., and Sarkar F.H. Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res. 65 (2005) 6934-6942
19. Ross J.A., and Kasum C.M. Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu. Rev. Nutr. 22 (2002) 19-34
20. Sarkar F.H., and Li Y. Mechanisms of cancer chemoprevention by soy isoflavone genistein. Cancer Metastasis Rev. 21 (2002) 265-280
21. Rahman K.M., Aranha O., Glazyrin A., Chinni S.R., and Sarkar F.H. Translocation of Bax to mitochondria induces apoptotic cell death in indole-3-carbinol (I3C) treated breast cancer cells. Oncogene 19 (2000) 5764-5771
22. Rahman K.M., Aranha O., and Sarkar F.H. Indole-3-carbinol (I3C) induces apoptosis in tumorigenic but not in nontumorigenic breast epithelial cells. Nutr. Cancer 45 (2003) 101-112
23. Verhoeven D.T., Verhagen H., Goldbohm R.A., van den Brandt P.A., and van P.G. A review of mechanisms underlying anticarcinogenicity by brassica vegetables. Chem. Biol. Interact. 103 (1997) 79-129
24. Hong C., Kim H.A., Firestone G.L., and Bjeldanes L.F. 3,3′-Diindolylmethane (DIM) induces a G(1) cell cycle arrest in human breast cancer cells that is accompanied by Sp1-mediated activation of p21(WAF1/CIP1) expression. Carcinogenesis 23 (2002) 1297-1305
25. Banerjee S., Wang Z., Kong D., and Sarkar F.H. In vivo molecular evidence of chemosensitization by 3,3-indolylmethane against pancreatic tumor. Pancreas (2007)
26. El-Rayes B.F., Ali S., Sarkar F.H., and Philip P.A. Cyclooxygenase-2-dependent and -independent effects of celecoxib in pancreatic cancer cell lines. Mol. Cancer Ther. 3 (2004) 1421-1426
27. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 441 (2006) 431-436
28. Tahara M. Recent advances in molecular-targeted drugs in head and neck cancer. Gan To Kagaku Ryoho 35 (2008) 745-752
29. Lee K.C., Lee S.H., Lee Y., Park S.H., Park J., Cho E.K., Shin D.B., Lee J.H., Kim D.Y., and Kim S.T. Prospective pilot study of consolidation chemotherapy with docetaxel and cisplatin after concurrent chemoradiotherapy for advanced head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 71 (2008) 187-191
30. Li Y., Chinni S.R., and Sarkar F.H. Selective growth regulatory and pro-apoptotic effects of DIM is mediated by AKT and NF-kappaB pathways in prostate cancer cells. Front Biosci. 10 (2005) 236-243
31. Fahy B.N., Schlieman M., Virudachalam S., and Bold R.J. AKT inhibition is associated with chemosensitisation in the pancreatic cancer cell line MIA-PaCa-2. Br. J. Cancer 89 (2003) 391-397
32. Fahy B.N., Schlieman M.G., Mortenson M.M., Virudachalam S., and Bold R.J. Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib. Cancer Chemother. Pharmacol. 56 (2005) 46-54
33. Abdelrahim M., Newman K., Vanderlaag K., Samudio I., and Safe S. 33′-Diindolylmethane (DIM) and its derivatives induce apoptosis in pancreatic cancer cells through endoplasmic reticulum stress-dependent upregulation of DR5. Carcinogenesis 27 (2006) 717-728
34. Savino III J.A., Evans J.F., Rabinowitz D., Auborn K.J., and Carter T.H. Multiple, disparate roles for calcium signaling in apoptosis of human prostate and cervical cancer cells exposed to diindolylmethane. Mol. Cancer Ther. 5 (2006) 556-563
35. Sun S., Han J., Ralph Jr. W.M., Chandrasekaran A., Liu K., Auborn K.J., and Carter T.H. Endoplasmic reticulum stress as a correlate of cytotoxicity in human tumor cells exposed to diindolylmethane in vitro. Cell Stress Chaperon. 9 (2004) 76-87
36. Harper M.E., Antoniou A., Villalobos-Menuey E., Russo A., Trauger R., Vendemelio M., George A., Bartholomew R., Carlo D., Shaikh A., Kupperman J., Newell E.W., Bespalov I.A., Wallace S.S., Liu Y., Rogers J.R., Gibbs G.L., Leahy J.L., Camley R.E., Melamede R., and Newell M.K. Characterization of a novel metabolic strategy used by drug-resistant tumor cells. FASEB J. 16 (2002) 1550-1557
37. Liang X.J., Finkel T., Shen D.W., Yin J.J., Aszalos A., and Gottesman M.M. SIRT1 contributes in part to cisplatin resistance in cancer cells by altering mitochondrial metabolism. Mol. Cancer Res. (2008)
38. Kumar B., Cordell K.G., D'Silva N., Prince M.E., Adams M.E., Fisher S.G., Wolf G.T., Carey T.E., and Bradford C.R. Expression of p53 and Bcl-xL as predictive markers for larynx preservation in advanced laryngeal cancer. Arch. Otolaryngol. Head Neck Surg. 134 (2008) 363-369
39. Li Y., Ellis K.L., Ali S., El-Rayes B.F., Nedeljkovic-Kurepa A., Kucuk O., Philip P.A., and Sarkar F.H. Apoptosis-inducing effect of chemotherapeutic agents is potentiated by soy isoflavone genistein, a natural inhibitor of NF-kappaB in BxPC-3 pancreatic cancer cell line. Pancreas 28 (2004) e90-e95
40. El-Rayes B.F., Ali S., Ali I.F., Philip P.A., Abbruzzese J., and Sarkar F.H. Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB. Cancer Res. 66 (2006) 10553-10559